Moomoo AI 已提取核心信息
On January 10, 2024, Senti Biosciences, Inc., a biotechnology company based in South San Francisco, California, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission. This filing is intended to register additional shares for the company's 2022 Equity Incentive Plan and 2022 Employee Stock Purchase Plan. Specifically, 2,287,751 additional shares of common stock are being registered for the Equity Incentive Plan, and 457,550 additional shares for the Employee Stock Purchase Plan. The company, which is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company, has incorporated by reference the contents of its previous Form S-8 filings from August 18, 2022, and February 16, 2023. The CEO and President, Timothy Lu, M.D., Ph.D., along with other executives and directors, have signed the registration statement, confirming the company's compliance with the requirements for filing on Form S-8.
On January 10, 2024, Senti Biosciences, Inc., a biotechnology company based in South San Francisco, California, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission. This filing is intended to register additional shares for the company's 2022 Equity Incentive Plan and 2022 Employee Stock Purchase Plan. Specifically, 2,287,751 additional shares of common stock are being registered for the Equity Incentive Plan, and 457,550 additional shares for the Employee Stock Purchase Plan. The company, which is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company, has incorporated by reference the contents of its previous Form S-8 filings from August 18, 2022, and February 16, 2023. The CEO and President, Timothy Lu, M.D., Ph.D., along with other executives and directors, have signed the registration statement, confirming the company's compliance with the requirements for filing on Form S-8.
2024年1月10日，总部位于加利福尼亚州南旧金山的生物技术公司Senti Biosciences, Inc. 向美国证券交易委员会提交了S-8表格的注册声明。该文件旨在为公司的2022年股权激励计划和2022年员工股票购买计划注册更多股份。具体而言，股权激励计划额外注册了2,287,751股普通股，员工股票购买计划又注册了457,550股普通股。该公司被归类为非加速申报人、小型申报公司和新兴成长型公司，已以引用方式纳入了其先前自2022年8月18日和2023年2月16日提交的S-8表格的内容。首席执行官兼总裁、医学博士、博士生Timothy Lu以及其他高管和董事签署了注册声明，确认公司遵守了提交S-8表格的要求。
2024年1月10日，总部位于加利福尼亚州南旧金山的生物技术公司Senti Biosciences, Inc. 向美国证券交易委员会提交了S-8表格的注册声明。该文件旨在为公司的2022年股权激励计划和2022年员工股票购买计划注册更多股份。具体而言，股权激励计划额外注册了2,287,751股普通股，员工股票购买计划又注册了457,550股普通股。该公司被归类为非加速申报人、小型申报公司和新兴成长型公司，已以引用方式纳入了其先前自2022年8月18日和2023年2月16日提交的S-8表格的内容。首席执行官兼总裁、医学博士、博士生Timothy Lu以及其他高管和董事签署了注册声明，确认公司遵守了提交S-8表格的要求。
有用
没用